Cite
HARVARD Citation
Milhem, M. et al. (n.d.). O85 Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab. Journal for immunotherapy of cancer. pp. A2-A3. [Online].